Targeting Ewing Sarcoma With ANTI-IL1RAP Chimeric Antigen Receptor Modified Ex-Vivo Expanded Natural Killer Cells (CAR TGFBI-NK) and TGF-BETA Imprinted NK Cells (CAR TGFBI-NK) in Combination With Dinutuximab and NKTR-255

Authors

Wen Luo, New York Medical CollegeFollow
Hai-Feng Zhang
Hai Hoang
Yaya Chu, New York Medical CollegeFollow
Janet Ayello, New York Medical CollegeFollow
Wei Li
Renata Scopim-Ribeiro
M M. Lizardo
M Rouleau
Dimiter S. Dimitrov
Deana Lee
Poul H. Sorensen
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

6-2023

DOI

10.1016/j.jbc.2023.103268

Journal Title

Pediatric Blood & Cancer

Department

Pathology, Microbiology and Immunology

Recommended Citation

Luo, W., Zhang, H., Hoang, H., Chu, Y., Ayello, J., Li, W., Scopim-Ribeiro, R., Lizardo, M. M., Rouleau, M., Dimitrov, D. S., Lee, D., Sorensen, P. H., & Cairo, M. S. (2023). Targeting Ewing Sarcoma With ANTI-IL1RAP Chimeric Antigen Receptor Modified Ex-Vivo Expanded Natural Killer Cells (CAR TGFBI-NK) and TGF-BETA Imprinted NK Cells (CAR TGFBI-NK) in Combination With Dinutuximab and NKTR-255. Pediatric Blood & Cancer, 70 (Suppl. 3), S205-S206. https://doi.org/10.1016/j.jbc.2023.103268